

share
Ahu-377 (Hemicalcium Salt) CAS NO 1369773-39-6
Unit Price:
CAS No.:1369773-39-6
Grade:Pharmacy Grade
Content:99.9%
Brand:Customizable
Packaging:Customizable
Description
Ahu-377 (Hemicalcium Salt) is a high-purity pharmaceutical intermediate, specifically the hemicalcium salt form of the active moiety. This compound is critical for ensuring precise formulation and optimal bioavailability in final drug products. It is primarily required by pharmaceutical R&D and manufacturing sectors for the development and production of cardiovascular and metabolic disease therapies.
Application
- Key intermediate in the synthesis of sacubitril, a component of the combination drug Entresto® (sacubitril/valsartan).
- Critical raw material for the production of angiotensin receptor-neprilysin inhibitor (ARNI) class pharmaceuticals.
- Used in cardiovascular disease research and drug development programs.
- Essential for process development and scale-up activities in API (Active Pharmaceutical Ingredient) manufacturing.
- Reference standard for analytical method development and quality control testing.
- Building block for related metabolic disorder therapeutic candidates.
Basic Information
| Product Name | Ahu-377 (Hemicalcium Salt) |
| CAS No. | 1369773-39-6 |
| Molecular Formula | C24H25CaN2O5 • xH2O |
| Molecular Weight | Contact for details |
| Synonyms | AHU-377 hemicalcium salt; Sacubitril calcium salt; LCZ696 intermediate; (2R,4S)-5-Biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid hemicalcium salt; Entresto intermediate; ARNI intermediate; LBQ657 calcium salt; Neprilysin inhibitor intermediate |
| EINECS | Contact for details |
Quality Control
Our Ahu-377 (Hemicalcium Salt) is manufactured under strict quality systems suitable for pharmaceutical use. Each batch is subjected to comprehensive analytical testing, including HPLC, NMR, and MS, to ensure identity, purity, and conformity to stringent specifications. Certificates of Analysis (COA) detailing all test results are provided and can be tailored to meet specific GMP, ICH Q7, or customer requirements.
Storage
Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This material is hygroscopic (moisture-sensitive) and must be kept in a dry environment. For long-term storage, consider desiccated conditions.
Specification
| Item | Specification |
|---|---|
| Appearance | White to off-white powder |
| Identification (IR) | Conforms to reference spectrum |
| Identification (HPLC) | Retention time matches reference standard |
| Assay (HPLC) | ≥98.0% (anhydrous basis) |
| Water Content (KF) | ≤5.0% |
| Related Substances (HPLC) | Total impurities ≤2.0% Any single impurity ≤0.5% |
| Residual Solvents (GC) | Complies with ICH Q3C guidelines |
| Heavy Metals | ≤20 ppm |
Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.
Hot Related Products


Pimobendan CAS NO 74150-27-9


Bemarinone CAS NO 16535-98-1


Saterinone (Hydrochloride) CAS NO 102685-83-6


Eplerenone CAS NO 107724-20-9


Cilobradine CAS NO 109859-50-9


Soluflazine CAS NO 112415-83-5


Ecadotril CAS NO 112573-73-6


L-Pimobendan CAS NO 118428-37-8


D-Pimobendan CAS NO 118428-38-9


Propionyl-L-Carnitine Hydrochloride CAS NO 119793-66-7


Hoe 065 CAS NO 123060-44-6


Candoxatrilat CAS NO 123122-54-3


Candoxatril CAS NO 123122-55-4


Bemoradan CAS NO 123169-88-0


Sezolamide CAS NO 123291-07-6


Candoxatrilat CAS NO 123898-42-0


Carsatrin CAS NO 125363-87-3


Ys-49 (Monohydrate) CAS NO 132836-42-1


Levosimendan CAS NO 141505-33-1


Ivabradine Hydrochloride CAS NO 148849-67-6
Why choose US
Trusted Manufacturer
With our own production facilities, we ensure consistent quality, reliable supply, and full traceability.
Rigorous Quality Assurance
Each batch undergoes strict QC, accompanied by COA, MSDS, and full compliance with international standards.
Advanced R&D Expertise
Our in-house lab drives process innovation, new product development, and tailored synthesis solutions.






